Cerebral tumors and multiple sclerosis (MS) can show overlapping clinical and magnetic resonance imaging (MRI) features and even occur concurrently. Due to the emergence of new symptoms, not usually MS related, an MRI was conducted in a 29-year-old woman with relapsing-remitting MS and showed a significant size progression of a parieto-occipital lesion, with mild clinical correlates, such as blurred vision, difficulty in speaking, and headache. Contrast-enhanced MRI and fluorothymidine positron-emission tomography (PET) did not point toward neoplasm, a lesion biopsy, however, showed astrocytoma, which was confirmed as grade III astrocytoma after the radical resection of the tumor. In the case of an atypical lesion, a tumor should be considered in patients with MS. A small fraction of high-grade gliomas show no enhancement on MRI and no hypermetabolism on PET. Biopsy proved to be the essential step in a successful diagnostic workup. To the best of our knowledge, this is the first case of anaplastic astrocytoma with these radiological features reported in a patient with MS.

Department of Neurology University Hospital Brno Brno Czechia

Department of Neurosurgery University Hospital Brno Brno Czechia

Department of Pathology University Hospital Brno Brno Czechia

Department of Radiology and Nuclear Medicine University Hospital Brno Brno Czechia

Department of Radiology Masaryk Memorial Cancer Institute Brno Czechia

Faculty of Medicine Masaryk University Brno Brno Czechia

Zobrazit více v PubMed

Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, et al. . The epidemiology of multiple sclerosis in Europe. Eur J Neurol. (2006) 13:700–22. 10.1111/j.1468-1331.2006.01342.x PubMed DOI

Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, et al. . Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain. (2019) 142:1858–75. 10.1093/brain/awz144 PubMed DOI PMC

Frederick MC, Cameron MH. Tumefactive demyelinating lesions in multiple sclerosis and associated disorders. Curr Neurol Neurosci Rep. (2016) 16:26. 10.1007/s11910-016-0626-9 PubMed DOI

Chandana SR, Movva S, Arora M, Singh T. Primary brain tumors in adults. Am Fam Physician. (2008) 77:1423–30. PubMed

Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Sorensen PS, et al. . A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Mult Scler. (2015) 21:294–304. 10.1177/1352458514564489 PubMed DOI PMC

Singh R, Stoltzfus KC, Chen H, Louie AV, Lehrer EJ, Horn SR, et al. . Epidemiology of synchronous brain metastases. Neurooncol Adv. (2020) 2:vdaa041. 10.1093/noajnl/vdaa041 PubMed DOI PMC

Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am. (2011) 22:1–6. 10.1016/j.nec.2010.08.007 PubMed DOI

Carrete LR, Young JS, Cha S. Advanced imaging techniques for newly diagnosed and recurrent gliomas. Front Neurosci. (2022) 16:787755. 10.3389/fnins.2022.787755 PubMed DOI PMC

Reagan TJ, Freiman IS. Multiple cerebral gliomas in multiple sclerosis. J Neurol Neurosurg Psychiatry. (1973) 36:523–8. 10.1136/jnnp.36.4.523 PubMed DOI PMC

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. . Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria'. Ann Neurol. (2005) 58:840–6. 10.1002/ana.20703 PubMed DOI

Salari N, Fatahian R, Kazeminia M, Hosseinian-Far A, Shohaimi S, Mohammadi M. Patients' survival with astrocytoma after treatment: a systematic review and meta-analysis of clinical trial studies. Indian J Surg Oncol. (2022) 13:329–42. 10.1007/s13193-022-01533-7 PubMed DOI PMC

Shin JY, Diaz AZ. Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy. J Neurooncol. (2016) 129:557–65. 10.1007/s11060-016-2210-1 PubMed DOI

Wahner HCW, Träger M, Bender K, Schweizer L, Onken J, Senger C, et al. . Predicting survival in anaplastic astrocytoma patients in a single-center cohort of 108 patients. Radiat Oncol. (2020) 15:282. 10.1186/s13014-020-01728-8 PubMed DOI PMC

Valiyaveettil D, Malik M, Joseph D, Ahmed SF, Kothwal SA. Prognostic factors and outcomes in anaplastic gliomas: an institutional experience. South Asian J Cancer. (2018) 7:1–4. PubMed PMC

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. . European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. (2017) 18:315–29. 10.1016/S1470-2045(17)30194-8 PubMed DOI

Timmermann C. ‘Just give me the best quality of life questionnaire': the Karnofsky scale and the history of quality of life measurements in cancer trials. Chronic Illn. (2013) 9:179–90. 10.1177/1742395312466903 PubMed DOI PMC

Ömerhoca S, Akkaş SY, Içen NK. Multiple sclerosis: diagnosis and differential diagnosis. Noro Psikiyatr Ars. (2018) 55:1–9. PubMed PMC

Chew SH, Achmad Sankala HB, Chew E, Md Arif MHB, Mohd Zain NR, Hashim H, et al. . Tumefactive demyelinating lesions versus CNS neoplasms, a comparative study. Mult Scler Relat Disord. (2023) 79:104992. 10.1016/j.msard.2023.104992 PubMed DOI

Lin X, Yu WY, Liauw L, Chander RJ, Soon WE, Lee HY, et al. . Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms. Neurol Clin Pract. (2017) 7:53–64. 10.1212/CPJ.0000000000000319 PubMed DOI PMC

Nakayama M, Naganawa S, Ouyang M, Jones KA, Kim J, Capizzano AA, et al. . A review of clinical and imaging findings in tumefactive demyelination. AJR Am J Roentgenol. (2021) 217:186–97. 10.2214/AJR.20.23226 PubMed DOI

Nikaki A, Angelidis G, Efthimiadou R, Tsougos I, Valotassiou V, Fountas K, et al. . 18F-fluorothymidine PET imaging in gliomas: an update. Ann Nucl Med. (2017) 31:495–505. 10.1007/s12149-017-1183-2 PubMed DOI PMC

Yamamoto Y, Ono Y, Aga F, Kawai N, Kudomi N, Nishiyama Y. Correlation of 18 F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas. J Nucl Med. (2012) 53:1911–5. 10.2967/jnumed.112.104729 PubMed DOI

Nowosielski M, DiFranco MD, Putzer D, Seiz M, Recheis W, Jacobs AH, et al. . An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS ONE. (2014) 9:e95830. 10.1371/journal.pone.0095830 PubMed DOI PMC

Muzi M, Spence AM, O'Sullivan F, Mankoff DA, Wells JM, Grierson JR, et al. . Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. J Nucl Med. (2006) 47:1612–21. PubMed

Malhotra HS, Jain KK, Agarwal A, Singh MK, Yadav SK, Husain M, et al. . Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Mult Scler. (2009) 15:193–203. 10.1177/1352458508097922 PubMed DOI

Boviatsis EJ, Kouyialis AT, Stranjalis G, Korfias S, Sakas DE. CT-guided stereotactic biopsies of brain stem lesions: personal experience and literature review. Neurol Sci. (2003) 24:97–102. 10.1007/s10072-003-0093-3 PubMed DOI